In ALK-positive NSCLC Nuvalent is starting a first-line phase 3, but the ROS1 path could be easier.

After a conference lacking the wow factor, biotech winners and losers emerge.

Efficacy with the group’s next-gen ALK and ROS1 inhibitors holds up, and first-line use could beckon.

NVL-330 features among the latest crop of industry projects newly into human trials.

ASP3082 grabs some early attention among degraders set to feature at ESMO.

The takeover of AnHeart centres on advancing the latter’s targeted lung cancer project taletrectinib.

After touting NVL-655 as being active in patients resistant to a third-generation ALK inhibitor, Nuvalent now has clinical data to back this up.